Fig. 2From: A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infectionClinical considerations for choosing between INSTIs. aCabotegravir has a higher genetic barrier to resistance than first generation INSTIs (RAL and EVG) with limited cross-resistance to these latter INSTIs; however, CAB may have a lower genetic barrier to resistance than other second generation INSTIs (DTG and BIC). BIC bictegravir, CAB cabotegravir, DTG dolutegravir, EVG elvitegravir, HBV hepatitis B virus, RAL raltegravir, STR single tablet regimen, TB tuberculosisBack to article page